TP53 and cancer: Antiproliferative properties were assessed using an aqueous non-radioactive cell proliferation method (Promega) against HepG2 (hepatocellular wild p53 type), as well as against HCT116 (p53+/+), HCT116 (p53−/−), and SW620 (mutant p53) cancer cell lines (Supplementary Figure S19).